Auriculasin
Based on 1 Customer Validation
Auriculasin is an anticancer agent that inhibits VEGFR2, PI3K/AKT/mTOR, MAPK. Auriculasin can inhibit cell proliferation, induce cell apoptosis, and inhibit angiogenesis, and promotes mitochondrial oxidative stress and ferroptosis. Auriculasin is also active at the cannabinoid receptor CB1 with an IC50 of 8.92 μM. Auriculasin can be used in cancer research, especially related diseases such as prostate cancer and non-small cell lung cancer, as well as research on the development of anti-angiogenic drugs.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.54%
- No. CAS: 60297-37-2
- Fòrmula: C25H24O6
- Peso molecular:420.45
-
Almacenamiento:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas VEGFR
More
Actividad biológica
|
CB1 8.92 μM (IC50) |
VEGFR2 |
Auriculasin (2.5-10 μM; 6-24 h) inhibits the proliferation of human umbilical vein endothelial cells (HUVECs) in a dose- and time-dependent manner[1].
Auriculasin (5-10 μM; 12 h) inhibits VEGF-induced migration and invasion of HUVECs[1].
Auriculasin (5-10 μM; 6 h) inhibits the formation of capillary-like structures in HUVECs[1].
Auriculasin (5-10 μM; 6 days) inhibits microvascular sprouting in rat aortic rings[1].
Auriculasin (5-10 μM; 24 h or 30 min-1 h) downregulates the expression of Bcl-2, Bcl-XL, and VEGF in HUVECs, and inhibits the phosphorylation of VEGFR2 and its downstream Akt, mTOR, etc.[1].
Auriculasin (2.5-10 μM; 24 h) inhibits the viability of RC-58T/h/SA#4 primary prostate cancer cells, and the effect is more significant when combined with TRAIL, and has low toxicity to RWPE-1 prostate epithelial cells[2].
Auriculasin (5 μM) combined with TRAIL (100 ng/mL; 24 h) induces apoptosis of RC-58T/h/SA#4 cells[2].
Auriculasin (1-10 μM; 24 h) reduces the viability of LNCa P prostate cancer cells and has no effect on RWPE-1 cells[3].
Auriculasin (1-5 μM; 24 h) induces apoptosis of LNCaP cells, which is manifested by an increase in the sub-G1 population and DNA fragmentation[3].
Auriculasin (2.5-5 μM; 12-24 h) increases ROS generation in LNCaP cells[3].
Auriculasin reduces NSCLC A549 cell viability and promotes mitochondrial oxidative stress and ferroptosis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVECs
-
Concentration:5 μM, 7.5 μM, 10 μM
-
Incubation Time:12 h
-
Result:Inhibited VEGF-induced migration in wound-healing assay and invasion in trans-well assay.
Auriculasin (5, 10 mg/kg; oral gavage; once every 2 days; 21 days) reduces tumor size, weight and volume in the nude mouse LNCaP prostate cancer xenograft model without significant toxicity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-week-old male C57BL/6 mice, Matrigel plug model[1]
-
Dosage:5 μg/mL, 10 μg/mL (in Matrigel with 20 units of heparin and 150 ng/mL VEGF)
-
Administration:Subcutaneous injection, single dose, 7 days
-
Result:Co-treated with Matrigel plugs and VEGF, showed marked reduction of red blood cells, lighter color, significantly reduced hemoglobin concentrations, dramatically blocked VEGF-induced vasculature formation, and reduced area of VEGF-staining cells compared to the VEGF alone group.
Chemical Information
-
No. CAS 60297-37-2
-
Appearance Solid
-
Peso molecular 420.45
-
Fòrmula C25H24O6
-
Color White to off-white
-
SMILES
O=C1C(C(O)=C(C=CC(C)(C)O2)C2=C3C/C=C(C)\C)=C3OC=C1C4=CC=C(O)C(O)=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Cho HD, et al. Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol. 2018 Nov;121:612-621. [Content Brief]
[2]. Cho HD, et al. Auriculasin sensitizes primary prostate cancer cells to TRAIL-mediated apoptosis through up-regulation of the DR5-dependent pathway. Food Chem Toxicol. 2019 Apr;126:223-232. [Content Brief]
[3]. Cho HD, et al. Auriculasin-induced ROS causes prostate cancer cell death via induction of apoptosis. Food Chem Toxicol. 2018 Jan;111:660-669. [Content Brief]
[4]. Wang X, et al. Auriculasin induces mitochondrial oxidative stress and drives ferroptosis by inhibiting PI3K/Akt pathway in non-small cell lung cancer. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):967-977. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Auriculasin Related Classifications
HY-N2911 Related Classifications
Powered by Bioz